Keynote speakers

Prof Dr Dr Sahm, MD, PhD, MBA is a board-certified neuropathologist, Vice-Chair of the Dept. of Neuropathology and Head of the Div. Molecular Neuropathology at Heidelberg University Hospital, Heidelberg, Germany. He is Full Professor of Neuropathology at University of Heidelberg, Faculty of the National Center for TumorDiseases (NCT) Germany, and co-speaker of the Molecular Diagnostics and Early Detection branch of the German Consortium for Translational Cancer Research (DKTK).

The research group he leads focuses on the identification of novel biomarkers for diagnosis, prognostication and prediction of response in brain tumors.

This approach has resulted in a variety of discoveries and assay developments with over 300 publications (first / senior author e.g. in Lancet Oncology, JCO, Nature Cancer, Nature Medicine).

Prof Sahm serves in several trials of the European Organization for Research and Treatment of Cancer (EORTC) as reference molecular neuropathologist. He is author of multiple guidelines for the German Societies of Neurology, Pathology, Neuropathology, or Radiooncology, the European Association of Neuro-oncology (EANO), the European Society of Medical Oncology (ESMO). Prof Sahm serves as member of the working group for the WHO classification, the cIMPACT Steering Committee of the International Society of Neuropathology, the ITCC-Brain Steering Committee, as chair of the EORTC-BTG Translational Research Committee, and formerly as member of the EANO Executive committee. He is also member of the National Expert Council for Accreditation and auditor for the German Accreditation Body.

Prof Sahm is co-founder of the academic spin-off Heidelberg Epignostix GmbH, a company founded 2023. Epignostix offers SaaMD-solutions based on their proprietary, patented approach of classifying tumors more accurately with a DNA methylation-based AI application.

Mathias Uhlen  research is focused on protein science, antibody engineering and precision medicine and ranges from basic  to more clinical research (https://www.scilifelab.se/researchers/mathias-uhlen/. Since 2003, he leads the Human Protein Atlas program. His research has resulted in more than 850 publications and more the 110,000 citations (h-index 144) according to Google Scholar. He is co-founder of 21 biotech companies and he was the Founding Director of the Science for Life Laboratory (SciLifeLab), a Swedish national infrastructure for molecular bioscience. He is member of several Swedish and international academies, including KVA, IVA and NAE (National Academy of Engineering, USA).

Pratiti (Mimi) Bandopadhayay, MBBS, PhD, is a pediatric neuro-oncologist and scientist within the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, an Associate Professor of Pediatrics at the Harvard Medical School, and an Institute Member of the Broad Institute of MIT and Harvard. She also serves as a faculty member for the Harvard Medical School PhD Program in Biological and Biomedical Sciences (BBS), and as the Director of the DFCI Pediatric Low-Grade Glioma Program. Mimi and the Bandopadhayay Lab apply genomic approaches to understand the drivers of pediatric brain tumors, and to identify therapeutic vulnerabilities.

www.bandolab.org